Reprint

Ophthalmic Drug Delivery, 2nd Edition

Edited by
October 2023
316 pages
  • ISBN978-3-0365-8799-8 (Hardback)
  • ISBN978-3-0365-8798-1 (PDF)

This book is a reprint of the Special Issue Ophthalmic Drug Delivery, 2nd Edition that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology
Summary

Research in ophthalmic drug delivery has developed significant advances in the few last years, and efforts have been made to develop more effective topical formulations to increase drug bioavailability, efficiency, and safety. Drug delivery to the posterior segment of the eye remains a great challenge in the pharmaceutical industry due to the complexity and particularity of the eye's anatomy and physiology. Some advances have been made with the purpose of maintaining constant drug levels in the site of action. The anatomical ocular barriers have a great impact on drug pharmacokinetics and, subsequently, on the pharmacological effect.Despite the increasing interest in efficiently reaching the posterior segment of the eye with reduced adverse effects, there is still a need to expand the knowledge of ocular pharmacokinetics that allow the development of safer and more innovative drug delivery systems. These novel approaches may greatly improve the lives of patients with ocular pathologies.

Format
  • Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
ocular; drug delivery; pharmacokinetics; tissue isolation; rat; eye; drug concentration; method; pigment; melanin; aniridia; ataluren; ophthalmic solution; rare disease; stability; tacrolimus; hydroxypropyl-β-cyclodextrin; topical ophthalmic administration; eye drops; uveitis; PET/CT imaging; ocular implants; electrospinning technique; glaucoma; sustained drug release; poly ε-caprolactone; electrospun fibers; permeability; retina; retinal pigment epithelium; Ussing chamber; intravitreal half-life; posterior capsule opacification; pathophysiology; wound healing; lens epithelial cells; intraocular lenses; experimental models; clinical studies; glaucoma; gold nanoparticles; anterior chamber; distribution; stability; intracameral injection; trabecular meshwork; hyaluronic acid; liposomes; intravitreal; ocular drug delivery; retinal explants; amantadine; blood–retinal barrier; drug delivery; retinal disease; NMDA receptor; inner BRB; retinal capitally endothelial cells; outer BRB; retinal pigment epithelial cells; transporter; rivoceranib; drug repositioning; microsphere; subfoveal choroidal neovascularization; macular degeneration; endotoxin-induced uveitis; tacrolimus; eye drops; hydroxypropyl-β-cyclodextrin; interleukins; immunosuppressants; tacrolimus; ophthalmic solution; physicochemical stability; container-content interaction; leachable compound; nanoparticles; PLGA; lactoferrin; topical ophthalmic administration; nanoprecipitation; protein nanocarriers; keratoconus; corneal ecstatic disorder; posterior capsular opacification; intraocular lens; surface modification; drug delivery; photothermal therapy; photodynamic therapy; micro-pattern; anti-biofouling; ocular hypertension; prostaglandin analogues; aqueous solubility; chemical stability; drug delivery; intraocular pressure; cystinosis; ophthalmic administration; cysteamine; compounded formulation; PET; nanocrystals; conjunctivitis; besifloxacin; Povacoat®; fluoroquinolones; acanthamoeba keratitis; controlled drug delivery; contact lens; miltefosine; PLGA